hematopoietic stemcell transplantation hsct transplantation multipotent hematopoietic stem cells usually derived bone marrow peripheral blood umbilical cord blood order replicate inside patient produce additional normal blood may autologous patients stem cells used allogeneic stem cells come donor syngeneic identical often performed patients certain cancers blood bone marrow multiple myeloma cases recipients immune system usually suppressed radiation chemotherapy transplantation infection graftversushost disease major complications allogeneic hsct remains dangerous procedure many possible complications reserved patients lifethreatening diseases survival following procedure increased use expanded beyond cancer autoimmune hereditary skeletal dysplasias notably malignant infantile indications stemcell transplantation many recipients hscts multiple leukemia would benefit prolonged treatment already resistant chemotherapy candidates hscts include pediatric cases patient inborn defect severe combined immunodeficiency congenital neutropenia defective stem cells also children adults aplastic lost stem cells birth treated stem cell transplants include sickle cell disease myelodysplastic syndrome neuroblastoma lymphoma ewings sarcoma desmoplastic small round cell tumor chronic granulomatous disease hodgkins disease syndrome nonmyeloablative socalled mini transplant microtransplantation procedures developed requiring smaller doses preparative chemotherapy radiation therapy allowing hsct conducted elderly patients would otherwise considered weak withstand conventional treatment first hscts recorded worldwide according global survey centers countries conducted worldwide network blood marrow transplantation autologous allogeneic family donors unrelated donors main indications transplant lymphoproliferative disorders leukemias many took place either europe americas worldwide network blood marrow transplantation reported millionth transplant undertaken december according world marrow donor association stemcell products provided unrelated transplantation worldwide increased bonemarrow donations peripheral blood stemcell donations cordblood autologous hsct requires extraction apheresis hematopoietic stem cells hscs patient storage harvested cells freezer patient treated highdose chemotherapy without radiotherapy intention eradicating patients malignant cell population cost partial complete bone marrow ablation destruction patients bone marrows ability grow new blood cells patients stored stem cells transfused hisher bloodstream replace destroyed tissue resume patients normal bloodcell autologous transplants advantage lower risk infection immunecompromised portion treatment since recovery immune function rapid also incidence patients experiencing rejection rare graftversushost disease impossible due donor recipient individual advantages established autologous hsct one standard secondline treatments diseases cancers acute myeloid leukemia though reduced mortality autogenous relative allogeneic hsct may outweighed increased likelihood cancer relapse related mortality allogeneic treatment may preferred researchers conducted small studies using nonmyeloablative hsct possible treatment type insulin dependent diabetes children adults results promising speculating whether experiments lead effective treatments diabetes autologous hsct effective treatment aggressive multiple type autologous hsct used multiple sclerosis treatment considered safe serious adverse events allogeneic hsct involves two people healthy donor patient recipient allogeneic hsc donors must tissue human leukocyte antigen hla type matches recipient matching performed basis variability three loci hla gene perfect match loci preferred even good match exists critical alleles recipient require immunosuppressive medications mitigate graftversushost disease allogeneic transplant donors may related usually closely hlamatched sibling syngeneic monozygotic identical twin patient necessarily extremely rare since patients identical twin offering source perfectly hlamatched stem cells unrelated donor related found close degree hla matching unrelated donors may found registry bonemarrow donors national marrow donor program nmdp us people would like tested specific family member friend without joining bonemarrow registry data banks may contact private hla testing laboratory tested blood test mouth swab see potential savior sibling may intentionally selected preimplantation genetic diagnosis match child regarding hla type free obvious inheritable disorder allogeneic transplants also performed using umbilical cord blood source stem cells general transfusing healthy stem cells recipients bloodstream reform healthy immune system allogeneic hscts appear improve chances cure longterm remission immediate transplantrelated complications compatible donor found additional hla testing blood potential donors hla genes fall two categories types ii general mismatches typei genes ie hlaa hlab hlac increase risk graft rejection mismatch hla type ii gene ie hladr increases risk graftversushost disease addition genetic mismatch small single dna base pair significant perfect matches require knowledge exact dna sequence genes donor recipient leading transplant centers currently perform testing five hla genes declaring donor recipient hlaidenticalcitation needed race ethnicity known play major role donor recruitment drives members ethnic group likely matching genes including genes least two commercialized allogeneic cell therapies developed prochymal omidubicel approved medical use united states april limit risks transplanted stemcell rejection severe graftversushost disease allogeneic hsct donor preferably hlatyping recipient allogeneic hsct recipients hlaidentical sibling even socalled perfect matches may mismatched minor alleles contribute graftversushost diseasecitation needed case bonemarrow transplant hscs removed large bone donor typically pelvis large needle reaches center bone technique referred bonemarrow harvest performed local general anesthesiacitation needed peripheral blood stem common source stem cells hsct collected blood process known apheresis donors blood withdrawn sterile needle one arm passed machine removes white blood cells red blood cells returned donor peripheral stem cell yield boosted daily subcutaneous injections granulocytecolony stimulating factor serving mobilize stem cells donors bone marrow peripheral circulationcitation needed extracting stem cells amniotic fluid possible autologous heterologous uses time childbirthcitation needed umbilical cord blood obtained mother donates infants umbilical cord placenta birth cord blood higher concentration hscs normally found adult blood small quantity blood obtained umbilical cord typically ml makes suitable transplantation small children adults newer techniques using ex vivo expansion cord blood units use two cord blood units different donors allow cord blood transplants used adultscitation needed cord blood harvested umbilical cord child born preimplantation genetic diagnosis hla matching see pgd hla matching donate ill sibling requiring hsctcitation needed leading cord blood banks include americord cord blood registry viacordcitation needed unlike organs bonemarrow cells frozen cryopreserved prolonged periods without damaging many cells necessity autologous hscs cells must harvested recipient months advance transplant treatment case allogeneic transplants fresh hscs preferred avoid cell loss might occur freezing thawing process allogeneic cord blood stored frozen cord blood bank obtainable time childbirth cryopreserve hscs preservative dimethyl sulfoxide must added cells must cooled slowly controlledrate freezer prevent osmotic cellular injury icecrystal formation hscs may stored years cryofreezer typically uses liquid nitrogencitation needed chemotherapy irradiation given immediately prior transplant called conditioning regimen purpose help eradicate patients disease prior infusion hscs suppress immune reactions bone marrow ablated destroyed doselevels cause minimal injury tissues allogeneic transplants combination cyclophosphamide total body irradiation conventionally employed treatment also immunosuppressive effect prevents rejection hscs recipients immune system posttransplant prognosis often includes acute chronic graftversushost disease may lifethreatening certain leukemias though coincide protection cancer relapse owing graftversustumor autologous transplants may also use similar conditioning regimens many chemotherapy combinations used depending type disease newer treatment approach nonmyeloablative allogeneic transplantation also termed reducedintensity conditioning ric uses doses chemotherapy radiation low eradicate bonemarrow cells instead nonmyeloablative transplants run lower risks serious infections transplantrelated mortality relying upon graft versus tumor effect resist inherent increased risk cancer also significantly requiring high doses immunosuppressive agents early stages treatment doses less conventional leads state mixed chimerism early transplant recipient donor hsc coexist bone marrow spacecitation needed decreasing doses immunosuppressive therapy allow donor tcells eradicate remaining recipient hscs induce graftversustumor effect effect often accompanied mild graftversushost disease appearance often surrogate marker emergence desirable graft versus tumor effect also serves signal establish appropriate dosage level sustained treatment low levels immunosuppressive agentscitation needed gentler conditioning regimens transplants associated lower risk transplantrelated mortality allow patients considered highrisk conventional allogeneic hsct undergo potentially curative therapy disease optimal conditioning strategy disease recipient fully established ric used elderly patients unfit myeloablative regimens higher risk cancer relapse may several weeks growth bone marrow expansion hscs progeny sufficient normalize blood cell counts reinitiate immune system offspring donorderived hscs documented populate many different organs recipient including heart liver muscle cells suggested abilities regenerating injured tissue organs however recent research shown lineage infidelity occur normal phenomenoncitation needed chimerism monitoring method monitor balance patients stem cells new stem cells donor cases patients stem cells increasing number treatment treatment may potentially worked intendedcitation needed hsct associated high treatmentrelated mortality recipient limits use conditions lifethreatening oneyear survival rate estimated roughly although figure includes deaths underlying disease well transplant major complications include venoocclusive disease mucositis infections sepsis graftversushost disease development new malignanciescitation needed bonemarrow transplantation usually requires recipients bone marrow destroyed myeloablation prior administration new cells engraftment patients may go several weeks without appreciable numbers white blood cells help fight infection puts patient high risk infections sepsis septic shock despite prophylactic antibiotics however antiviral medications acyclovir valacyclovir quite effective prevention hsctrelated outbreak herpetic infection seropositive immunosuppressive agents employed allogeneic transplants prevention treatment graftversushost disease increase risk opportunistic infection immunosuppressive drugs given minimum six months transplantation much longer required treatment graftversushost disease transplant patients lose acquired immunity example immunity childhood diseases measles polio transplant patients must retreated childhood vaccines immunosuppressive medicationscitation needed severe liver injury result hepatic venoocclusive disease vod newly termed sinusoidal obstruction syndrome elevated levels bilirubin hepatomegaly fluid retention clinical hallmarks condition appreciation generalized cellular injury obstruction hepatic vein sinuses greater severe cases sos associated high mortality rate anticoagulants defibrotide may effective reducing severity vod may also increase bleeding complications ursodiol shown help prevent vod presumably facilitating flow bile injury mucosal lining mouth throat common regimenrelated toxicity following ablative hsct regimens usually lifethreatening painful prevents eating drinking mucositis treated pain medications plus intravenous infusions prevent dehydration malnutritioncitation needed mucosal lining bladder affected children undergoing hsct causes hematuria blood urine frequent urination abdominal pain graftversushost disease gvhd inflammatory disease unique allogeneic transplantation attack new bone marrows immune cells recipients tissues occur even donor recipient hlaidentical immune system still recognize differences tissues named graftversushost disease bonemarrow transplantation transplant procedure transplanted cells must accept body rather body accepting new acute gvhd typically occurs first three months transplantation may involve skin intestine liver highdose corticosteroids prednisone standard treatment immunosuppressive treatment often leads deadly infections chronic gvhd may also develop allogeneic transplant major source late treatmentrelated complications although less often results death addition inflammation chronic gvhd may lead development fibrosis scar tissue similar scleroderma may cause functional disability require prolonged immunosuppressive therapy gvhd usually mediated cells react foreign peptides presented major histocompatibility complex hostcitation needed research needed determine whether mesenchymal stromal cells use prophylaxis treatment graftversustumor effect gvt graft versus leukemia effect beneficial aspect gvhd phenomenon example hsct patients either acute particular chronic gvhd allogeneic transplant tend lower risk cancer due therapeutic immune reaction grafted donor lymphocytes diseased bone marrow recipient lower rate relapse accounts increased success rate allogeneic transplants compared transplants identical twins indicates allogeneic hsct form immunotherapy gvt major benefit transplants employ highest immunosuppressive regimens graft versus tumor mainly beneficial diseases slow progress eg chronic leukemia lowgrade lymphoma cases multiple myeloma less effective rapidly growing acute cancer relapses hsct another transplant performed infusing patient greater quantity donor white blood cells donor lymphocyte patients hsct higher risk oral carcinoma posthsct oral cancer may aggressive behavior poorer prognosis compared oral cancer nonhsct metaanalysis showed risk secondary cancers bone cancer head neck cancers melanoma standardized incidence ratios respectively significantly increased hsct diagnostic tests cancers included screening program patients prevention early detection prognosis hsct varies widely dependent upon disease type stage stemcell source hlamatched status allogeneic hsct conditioning regimen transplant offers chance cure longterm remission inherent complications graft versus host disease immunosuppressive treatments spectrum opportunistic infections recent years survival rates gradually improving across almost populations subpopulations receiving mortality allogeneic stem cell transplantation estimated using prediction model created sorror et using hematopoietic cell transplantationspecific comorbidity index hctci hctci derived validated investigators fred hutchinson cancer research center us hctci modifies adds wellvalidated comorbidity index charlson comorbidity index cci charlson et cci previously applied patients undergoing allogeneic hct appears provide less survival prediction discrimination hctci scoring system patients successfully treated hsct total body irradiation childhood found increased fat mass percentage leading significantly decreased exercise capacity adulthood suggests patients underwent successful treatment hsct increased predisposition cardiovascular disease later risks complication depend patient characteristics health care providers apheresis procedure colonystimulating factor used gcsf gcsf drugs include filgrastim neupogen neulasta lenograstim graslopin filgrastim typically dosed microgramkg level days harvesting stem cells documented adverse effects filgrastim include splenic rupture acute respiratory distress syndrome alveolar hemorrhage allergic reactions usually experienced first addition platelet hemoglobin levels dip postprocedurally returning normal question whether geriatrics patients react patients sufficiently examined coagulation issues inflammation atherosclerotic plaques known occur result gcsf injection gcsf also described induce genetic changes agranulocytes normal statistically significant evidence either hypothesis myelodysplasia mds acute myeloid leukaemia aml induced gcsf susceptible blood drawn peripheral vein majority patients central line jugular subclavian femoral veins may used adverse reactions apheresis experienced women men adverse events primarily consisted numbnesstingling multiple line attempts study involving donors aged years indicated bone pain primarily back hips result filgrastim treatment observed donation recommended history back symptoms observed percent donors include muscle pain headache fatigue difficulty symptoms returned baseline month donation majority one metastudy incorporated data donors patients reported adverse side effects peripheral blood side effects included pain prior collection procedure result gcsf injections postprocedural generalized skeletal pain fatigue reduced study surveyed donors found serious adverse events requiring prolonged hospitalization occurred donors rate although none events donors observed higher normal rates cancer years one study based survey medical teams covered peripheral blood hsct cases found serious cardiovascular adverse reaction rate one study reported cardiovascularrelated fatality risk within first days hsct two woman aplastic anaemia received first human bone marrow transfusion patient received regular blood transfusions attempt made increase leukocyte platelet counts intravenous bone marrow injection without unexpected stemcell transplantation pioneered using bone marrowderived stem cells team fred hutchinson cancer research center led e donnall thomas whose work later recognized nobel prize physiology medicine thomas work showed bonemarrow cells infused intravenously could repopulate bone marrow produce new blood cells work also reduced likelihood developing lifethreatening graftversushost collaborating eloise giblett professor university washington discovered genetic markers could confirm donor matches first physician perform successful human bonemarrow transplant disease cancer robert good university minnesota john kersey also university minnesota performed first successful bonemarrow transplant cure lymphoma patient today longestliving lymphoma transplant end million people registered willingness bonemarrow donor one registries countries participating bone marrow donors worldwide around million registered donors abdr typed allowing easy matching cord blood units received one cord blood banks countries participating highest total number bonemarrow donors registered us million highest number per capita cyprus within us racial minority groups least likely registered least likely find potentially lifesaving match six african americans able find bonemarrow match six common european genetic africans genetically diverse people european descent means registrations needed find match bone marrow cord blood banks exist south africa new program beginning many people belonging different races requested donate shortage donors exists african mixed race latino aboriginal many communities two registries us recruit unrelated allogeneic donors nmdp match gift life marrow registry team doctors berlin germany including gero h√ºtter performed stemcell transplant leukemia patient timothy ray brown also matching donors selected homozygous individual two genetic copies rare variant cell surface receptor genetic trait confers resistance hiv infection blocking attachment hiv cell roughly one people european ancestry inherited mutation rarer transplant repeated year later leukemia relapse three years initial transplant despite discontinuing antiretroviral therapy researchers detect hiv transplant recipients blood various biopsies levels hivspecific antibodies also declined leading speculation patient may functionally cured hiv scientists emphasise unusual potentially fatal transplant complications berlin patient developed graftversushost disease leukoencephalopathy mean procedure could performed others hiv even sufficient numbers suitable donors daniel kuritzkes reported results two stemcell transplants patients hiv however use donors deletion transplant procedures put antiretroviral therapies neither showed traces hiv blood plasma purified cells using sensitive culture method less copiesml virus detected patients time discontinuation british man became second cleared hiv receiving bonemarrow transplant virusresistant donor patient called london patient reference famous berlin since mcallisters report patient multiple sclerosis ms received bonemarrow transplant chronic myelogenous leukemia reports published describing hscts performed primarily shown reduce eliminate ongoing clinical relapses halt progression reduce burden disability patients aggressive highly active ms absence chronic treatment diseasemodifying randomized clinical trial including patients showed hsct significantly prolonged time disease progression compared diseasemodifying longterm outcome patients severe disease showed complete disease remission hsct hsct also used treating selected severe cases autoimmune neurological diseases neuromyelitis optica chronic inflammatory demyelinating polyneuropathy myasthenia httpsenwikipediaorgwikihematopoieticstemcelltransplantation